BURST is an innovative incubation program for high-potential medical technology startups and scale-ups that will position London as a focal point for life science innovation. The program will provide intensive support to 30 companies, including approximately $3 million in cash and in-kind support.
Each of BURST’s three cohorts will include ten companies, primarily from the life science, medical device and health information technology fields. Each 12-month cohort will focus on four main pillars: market validation, company structure, IP, and investor readiness.
April 1, 2017 – March 31, 2018
Application deadline: March 7, 2017
August 1, 2017 – July 31, 2018
Application deadline: July 1, 2017
December 1, 2017 – November 30, 2018
Application deadline: November 1, 2017
Each participating company will receive $30,000 in funding, plus $10,000 for professional development provided by TechAlliance. Approved life science companies will also receive $30,000 from the London Medical Network, for a total of $70,000.
To qualify for London Medical Network funding, BURST participants will be obligated to maintain a presence in London for a minimum of 24 months after the conclusion of their cohort.
BURST By the Numbers
Approximate value of total cash and in-kind investment through BURST
Participating companies over three cohorts
BURST cash investment available to qualifying companies, plus significant in-kind support
BURST Program Structure
Prospective companies will complete an online application form outlining their technologies and proposed use of funds that will be reviewed and accepted by a panel of experts.
Space & Programming
Each company will be provided shared workshop and a common area for programming and cohort-specific learning activities.
Each company will work closely with experts in market research, corporate structure and IP to determine gaps in their company or technology.
Each company will work with a mentor to finalzie their plans, then meet on a bi-weekly basis to monitor progress and receive guidance.
Each cohort will conclude with a Demo Day, showcasing their technologies to investors and industry representatives.
BURST Cohort #1 Companies
Aufero Medical Technologies have developed a device for the treatment of cardiac arrhythmia. The device will maintain contact force at a specified level during the procedure, reducing arrhythmia recurrence and repeat surgery.
CryoCaddy has developed an innovative device and technique for frozen section embedding, a common procedure used in pathology labs. The system will improve patient care by providing labs with unprecedented efficiencies and time savings.
Designer Microbes creates custom microbial strains, which will have applications across a variety of industries, including enabling the production of medicines, DNA storage technologies, food, and next-generation fuels.
Digital Medical Experts have developed a technology that uses conventional EEG data to help physicians effectively diagnose and treat patients with major depression, bipolar disorder, and schizophrenia.
Epineuron Technologies have developed a peripheral nerve care technology using innovative electrical stimulation. Their device can be used during surgery to locate, identify, and stimulate the injured nerve.
Front Line Medical Technologies have created an all-in-one device for temporary control of excessive bleeding in emergency medical situations. This device will control truncal hemorrhaging until the patient can receive appropriate, life-saving surgical care.
Parallax Innovations have developed hardware and software to increase the functionality of existing CT imaging machines.
Spectral Devices creates multispectral cameras using patent-pending technology for biomedical research, farming, factory automation, and aerospace. These compact and cost-effective devices can be used to detect human disease, improve crop yield, ensure product quality and manage the earth’s resources.
TopSpin360 have created a patented training device that helps prevent concussion risk by improving neck strength and function. Strengthening the neck reduces the whiplash effect of a blow to the body, which is a leading cause of concussions, not just a direct impact to the head.
Triage is an app powered by artificial intelligence that can instantly diagnose skin disorders with beyond dermatologist-level accuracy.